

FILE 'HOME' ENTERED AT 09:33:32 ON 01 SEP 2004

=> file reg
=> e dimethyl(5a)cholesta(10a)triene(5a)ol/cn
E1 1 DIMETHYL(5-NITRO-2-FUROYL METHYL)SULFONIUM BROMIDE, (2,4-DINITROPHENYL)HYDRAZONE/CN
E2 1 DIMETHYL(5-SULFO-8-QUINOLYL)SULFONIUM HYDROXIDE, INNER SALT/CN
E3 0 --> DIMETHYL(5A)CHOLESTA(10A)TRIENE(5A)OL/CN
E4 1 DIMETHYL(6-((5-NITROPYRIDIN-2-YL)OXY)-2-PHENYLCHROMAN-4-YL)AMINE/CN
E5 1 DIMETHYL(6-(2-PHENYLCHROMAN-6-YLOXY)PYRIDIN-3-YL)AMINE/CN
E6 1 DIMETHYL(6-ACETOXY-1-ISOPROPENYL-4-METHYLHEXYL)SULFONIUM PERCHLORATE/CN
E7 1 DIMETHYL(6-ACETOXY-2,6-DIMETHYLOCTA-1,7-DIEN-3-YL)SULFONIUM PERCHLORATE/CN
E8 1 DIMETHYL(6-METHYLCHOLEST-5-EN-3B-YL)SULFONIUM P-TOLUENE SULFONATE/CN
E9 1 DIMETHYL(6-OXO-5A-CHOLESTAN-3B-YL)SULFONIUM CHLORIDE/CN
E10 1 DIMETHYL(6-OXO-5A-CHOLESTAN-3B-YL)SULFONIUM P-TOLUENE SULFONATE/CN
E11 1 DIMETHYL(6-PHENANTHRIDINYL METHYL)SULFONIUM CHLORIDE/CN
E12 1 DIMETHYL(6-PHENYLCHOLEST-5-EN-3B-YL)SULFONIUM P-TOLUENE SULFONATE/CN

=> e dimethyl-5a-cholesta-8,14,24-triene-3b-ol/cn
E1 1 DIMETHYL-5-(DIMETHYLAMINO)ISOPHTHALATE-TETRAETHYLENE GLYCOL POLYMER, SRU/CN
E2 1 DIMETHYL-5-HEXENYLSILOXY-TERMINATED DIMETHYLPOLYSILOXANE, SRU/CN
E3 0 --> DIMETHYL-5A-CHOLESTA-8,14,24-TRIENE-3B-OL/CN
E4 1 DIMETHYL-6-PHENANTHRIDINYLCARBINOL/CN
E5 1 DIMETHYL-7-NORBORNYLIDENEAMMONIUM PERCHLORATE/CN
E6 1 DIMETHYL-7-OCTENYLSILANOL/CN
E7 1 DIMETHYL-9,10-DIHYDRO-10-METHYL-9-OXO-12H-JULOIDINO(8,9-B)QUINOLINO(3,4-E)PYRAN-12-YLIDENEDIMETHYLIMINIUM CHLORIDE/CN
E8 1 DIMETHYL-9,10-PHENANTHRENEDICARBOXYLIC ANHYDRIDE/CN
E9 1 DIMETHYL-9H-XANTHENE/CN
E10 1 DIMETHYL-CARBOXY-METHYL-SELENIUM BROMIDE/CN
E11 1 DIMETHYL-D-CHONDROCURARINE DICHLORIDE/CN
E12 1 DIMETHYL-D-TUBOCURARINE/CN

=> file ca
=> s dimethyl(5a)cholesta(10a)triene(5a)ol
321014 DIMETHYL
38 DIMETHYLS
321032 DIMETHYL
(DIMETHYL OR DIMETHYLS)
1916 CHOLESTA
10688 TRIENE
1847 TRIENES
11840 TRIENE
(TRIENE OR TRIENES)
104381 OL
4426 OLS
107035 OL
(OL OR OLS)
L1 2 DIMETHYL(5A)CHOLESTA(10A)TRIENE(5A)OL

=> d ind 1-2

L1 ANSWER 1 OF 2 CA COPYRIGHT 2004 ACS on STN

IC ICM A61K031-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 2
ST meiosis activating sterol soln fertilization; protein solubilization
meiosis activating substance; phosphoglyceride solubilization meiosis
activating sterol
IT Egg
(germinal vesicle, breakdown; solns. containing meiosis-activating
substance and additive for in vitro fertilization)
IT Fertilization
(in vitro; solns. containing meiosis-activating substance and additive for
in vitro fertilization)
IT Egg
(oocyte; solns. containing meiosis-activating substance and additive for in
vitro fertilization)
IT Albumins, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(serum; solns. containing meiosis-activating substance and additive for in
vitro fertilization)
IT Sterols
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PEP (Physical, engineering or chemical process); THU
(Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(solns. containing meiosis-activating sterols and additive for in vitro
fertilization)
IT Meiosis
(solns. containing meiosis-activating substance and additive for in vitro
fertilization)
IT Glycerophospholipids
Proteins, general, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(solns. containing meiosis-activating substance and additive for in vitro
fertilization)
IT Drug delivery systems
(solns.; solns. containing meiosis-activating substance and additive for in
vitro fertilization)
IT 516-72-3 19431-20-0 64284-64-6 174351-75-8 250256-71-4
330432-44-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(solns. containing meiosis-activating substance and additive for in vitro
fertilization)
L1 ANSWER 2 OF 2 CA COPYRIGHT 2004 ACS on STN
CC 2-0 (Mammalian Hormones)
Section cross-reference(s): 13
ST review meiosis activating sterol fertility mammal
IT Fertility
Meiosis
(meiosis activating sterols and fertility in mammals and man)
IT 7448-02-4 64284-64-6
RL: BAC (Biological activity or effector, except adverse); BOC (Biological
occurrence); BSU (Biological study, unclassified); MFM (Metabolic
formation); THU (Therapeutic use); BIOL (Biological study); FORM
(Formation, nonpreparative); OCCU (Occurrence); USES (Uses)
(meiosis activating sterols and fertility in mammals and man)

=> FIL REGISTRY

=> S 7448-02-4/RN

=>

=> FIL REGISTRY

=> S 64284-64-6/RN

L3 1 64284-64-6/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L3 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 5.92 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 64284-64-6 REGISTRY

CN Cholesta-8,14,24-trien-3-ol, 4,4-dimethyl-, (3 β ,5 α)- (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 4,4-Dimethyl-5 α -cholesta-8,14,24-trien-3 β -ol

CN FF-MAS

FS STEREOSEARCH

MF C29 H46 O

LC STN Files: BEILSTEIN*, BIOSIS, CA, CANCERLIT, CAPLUS, CASREACT, MEDLINE,
TOX CENTER, USPATFULL

(*File contains numerically searchable property data)

DT.CA CPlus document type: Journal; Patent


RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP
(Preparation); PROC (Process); PRP (Properties); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
(Preparation); PROC (Process); PRP (Properties); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: PREP (Preparation)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

73 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

73 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file ca

=> d 11 bib abs 1-2

L1 ANSWER 1 OF 2 CA COPYRIGHT 2004 ACS on STN
 AN 134:242674 CA
 TI Composition for in vitro IVF containing a meiosis-activating substance
 IN Andersen, Tina Meinertz
 PA Novo Nordisk A/s, Den.
 SO PCT Int. Appl., 11 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019354	A2	20010322	WO 2000-DK500	20000911
	WO 2001019354	A3	20010614		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1216059	A2	20020626	EP 2000-958274	20000911
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000014058	A	20040330	BR 2000-14058	20000911
	ZA 2002001383	A	20020906	ZA 2002-1383	20020219
	NO 2002001309	A	20020315	NO 2002-1309	20020315

PRAI DK 1999-1308 A 19990916
 WO 2000-DK500 W 20000911
 AB A composition useful in connection with in vitro fertilization (IVF) based on a solid meiosis-activating substance (MAS) or a derivative thereof with low solubility is described. A MAS can be dissolved in an aqueous medium using an additive, e.g., a protein or a phosphoglyceride, to obtain a solution containing

at least 0.001 µg/mL and not more than 0.1 g/mL of MAS. For example, solns. were prepared by mixing (a) 100 µL of ethanolic 4,4-dimethyl-5α-cholesta-8,14,24-triene-3β-ol (FF-MAS) containing 5.22, 2.5, or 0.5 µg/mL FF-MAS and (b) 250 µL of 20% aqueous human serum albumin (HSA) in the ratio of FF-MAS to HSA of 1:10,000, 1:6667, and 1:2000, resp., and tested on oocytes obtained from immature female mice. Percent of germlinal vesicle breakdown (GVB) for the formulations prepared were 78, 82, and 90%, resp.

L1 ANSWER 2 OF 2 CA COPYRIGHT 2004 ACS on STN
 AN 132:73693 CA
 TI Meiosis activating sterols (MAS) and fertility in mammals and man
 AU Byskov, Anne Grete; Andersen, Claus Yding; Leonardsen, Lise; Baltsen, Morgens
 CS Laboratory of Reproductive Biology, Juliane Marie Center for Children, Women and Reproduction, University Hospital of Copenhagen, Copenhagen, DK-2100, Den.
 SO Journal of Experimental Zoology (1999), 285(3), 237-242
 CODEN: JEZOAO; ISSN: 0022-104X
 PB Wiley-Liss, Inc.
 DT Journal; General Review
 LA English

AB A review with .apprx.35 refs. In mammals two meiosis activating sterols (MAS) have been found to activate meiotic resumption in mouse oocytes, in vitro. FF-MAS (4,4-dimethyl-5 α -cholesta-8,14,24-triene-3 β -ol) was extracted from human preovulatory follicular fluid and T-MAS (4,4-dimethyl-5 α -cholest-8,24-diene-3 β -ol) from bull testicular tissue. Quite unexpected, these two sterols, which introduce the cholesterol biosynthetic pathway from lanosterol, may be locally acting substances with important physiol. function for reproduction FF-MAS and T-MAS are present in the preovulatory follicular fluid of different mammalian species and have the capacity to initiate resumption of meiosis in mouse oocyte cultured in the presence of hypoxanthine, a natural meiosis maturation inhibitor. FF-MAS is produced by the cumulus cells of intact oocyte-cumulus complexes upon FSH-stimulation and provides the oocyte with a go-signal for the resumption of meiosis. T-MAS constitutes the vast majority of MAS found in the mammalian testis and in the human ejaculate; in particular a high concentration is found in the spermatozoa. T-MAS may be produced by the spermatids and the presence of T-MAS in spermatozoa may suggest that T-MAS plays a role in fertilization by affecting the second meiotic division.

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg
=> sel 13 name
E1 THROUGH E2 ASSIGNED

=> index bioscience

74 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s e1-2 or 64284-64-6
2 FILE ADISINSIGHT
1 FILE AGRICOLA
49 FILE BIOSIS
12 FILES SEARCHED...
9 FILE BIOTECHABS
9 FILE BIOTECHDS
23 FILE BIOTECHNO
17 FILE CABA
2 FILE CANCERLIT
17 FILES SEARCHED...
88 FILE CAPLUS
1 FILE CEABA-VTB
1 FILE CONFSCI
1 FILE DISSABS
1 FILE DDFU
27 FILES SEARCHED...
100 FILE DGENE
3 FILE DRUGU
2 FILE EMBAL
38 FILE EMBASE
32 FILE ESBIOBASE
36 FILES SEARCHED...
9 FILE IFIPAT
3 FILE LIFESCI
48 FILES SEARCHED...
49 FILE MEDLINE
22 FILE PASCAL
55 FILES SEARCHED...
1 FILE PHAR
1 FILE PROUSDDR

```

42 FILE SCISEARCH
5 FILE TOXCENTER
66 FILES SEARCHED...
29 FILE USPATFULL
3 FILE USPAT2
1 FILE VETU
71 FILES SEARCHED...
27 FILE WPIDS
72 FILES SEARCHED...
27 FILE WPINDEX

31 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L4 QUE (FF-MAS/BI OR "4,4-DIMETHYL-5A-CHOLESTA-8,14,24-TRIEN-3B-OL
"/BI) OR 64284-64-6

=> s 14 and solid
13 FILES SEARCHED...
2 FILE CAPLUS
18 FILES SEARCHED...
29 FILES SEARCHED...
36 FILES SEARCHED...
44 FILES SEARCHED...
54 FILES SEARCHED...
55 FILES SEARCHED...
66 FILES SEARCHED...
13 FILE USPATFULL
3 FILE USPAT2
70 FILES SEARCHED...
2 FILE WPIDS
72 FILES SEARCHED...
2 FILE WPINDEX

5 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L5 QUE L4 AND SOLID

=> d rank
F1 13 USPATFULL
F2 3 USPAT2
F3 2 CAPLUS
F4 2 WPIDS
F5 2 WPINDEX

=> file hits
=> s 15
3 FILES SEARCHED...
L6 20 L5

=> dup rem 16
PROCESSING COMPLETED FOR L6
L7 15 DUP REM L6 (5 DUPLICATES REMOVED)
ANSWERS '1-13' FROM FILE USPATFULL
ANSWERS '14-15' FROM FILE CAPLUS

=> s 17 and (protein or polypeptide or phosphoglycer?)
L8 6 L7 AND (PROTEIN OR POLYPEPTIDE OR PHOSPHOGLYCER?)

=> dup rem 18
PROCESSING COMPLETED FOR L8
L9 6 DUP REM L8 (0 DUPLICATES REMOVED)
ANSWERS '1-4' FROM FILE USPATFULL
ANSWERS '5-6' FROM FILE CAPLUS

```

=> d bib 1-4

L9 ANSWER 1 OF 6 USPATFULL on STN
AN 2002:299266 USPATFULL
TI Composition for IVF
IN Andersen, Tina Meinertz, Horsholm, DENMARK
Muller, Lars Klingberg, Ballerup, DENMARK
PI US 2002166789 A1 20021114
AI US 2002-68224 A1 20020205 (10)
PRAI DK 2001-189 20010206
DK 2001-382 20010308
US 2001-273162P 20010302 (60)
DT Utility
FS APPLICATION
LREP Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405
Lexington Avenue, New York, NY, 10174-6401
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 643
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 6 USPATFULL on STN
AN 2002:235463 USPATFULL
TI Follicle stimulating hormones
IN Schambye, Hans Thalsgard, Frederiksberg, DENMARK
Andersen, Kim Vilbour, Copenhagen, DENMARK
Hazel, Bart van den, Copenhagen, DENMARK
Christiansen, Jesper, Lyngby, DENMARK
Jeppesen, Claus Bekker, Nivaa, DENMARK
PI US 2002127652 A1 20020912
AI US 2001-780933 A1 20010209 (9)
PRAI DK 2000-220 20000211
DK 2000-1092 20000714
US 2000-184035P 20000222 (60)
US 2000-225558P 20000816 (60)
DT Utility
FS APPLICATION
LREP LAW OFFICES OF JONATHAN ALAN QUINE, P O BOX 458, ALAMEDA, CA, 94501
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 3427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 6 USPATFULL on STN
AN 2002:99135 USPATFULL
TI Mycobacterium tuberculosis CYP51 **polypeptides** and nucleic
acids and therapeutic and screening methods relating to same
IN Waterman, Michael R., Nashville, TN, UNITED STATES
Bellamine, Aouatef, Nashville, TN, UNITED STATES
PI US 2002052031 A1 20020502
AI US 2001-909903 A1 20010720 (9)
RLI Division of Ser. No. US 1999-345218, filed on 30 Jun 1999, ABANDONED
DT Utility
FS APPLICATION
LREP JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3776
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 6 USPATFULL on STN
AN 2002:54621 USPATFULL

TI Mycobacterium tuberculosis CYP51 high resolution structure,
 polypeptides and nucleic acids, and therapeutic and screening
 methods relating to same
 IN Waterman, Michael R., Nashville, TN, UNITED STATES
 Bellamine, Aouatef, Nashville, TN, UNITED STATES
 Podust, Larissa M., Hermitage, TN, UNITED STATES
 PI US 2002031782 A1 20020314
 AI US 2001-796138 A1 20010228 (9)
 RLI Continuation-in-part of Ser. No. US 1999-345218, filed on 30 Jun 1999,
 ABANDONED
 DT Utility
 FS APPLICATION
 LREP JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707
 CLMN Number of Claims: 42
 ECL Exemplary Claim: 1
 DRWN 14 Drawing Page(s)
 LN.CNT 16055
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d bib abs hit 5-6

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:615351 CAPLUS
 DN 137:150623
 TI Process and container with low oxygen content and containing a stable MAS
 (meiosis activation substances) composition for increasing the fertility
 of oocytes and use in IVF or IVM
 IN Mueller, Lars Klingberg; Andersen, Tina Meinertz
 PA Novo Nordisk A/S, Den.
 SO PCT Int. Appl., 22 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062287	A1	20020815	WO 2002-DK35	20020117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1359881	A1	20031112	EP 2002-715376	20020117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004525676	T2	20040826	JP 2002-562295	20020117
	US 2002166789	A1	20021114	US 2002-68224	20020205
PRAI	DK 2001-189	A	20010206		
	US 2001-273162P	P	20010302		
	DK 2001-382	A	20010308		
	WO 2002-DK35	W	20020117		

AB A solid, stable composition containing a meiosis activating substance can
 be prepared by adding a protein or a phosphoglyceride in
 the presence of an atmospheric having a low content of oxygen, for example in
 vacuo. A closed container having a low content of oxygen and further
 containing MAS is claimed. More specifically, a closed container having a low
 content of oxygen and further containing a solid composition with high
 aqueous solubility comprising MAS and an additive is claimed. Also claimed is
 a process for preparing a closed container having a low content of oxygen and

further containing a **solid** composition comprising MAS and an additive.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB A **solid**, stable composition containing a meiosis activating substance can be prepared by adding a **protein** or a **phosphoglyceride** in the presence of an atmospheric having a low content of oxygen, for example in vacuo. A closed container having a low content of oxygen and further containing MAS is claimed. More specifically, a closed container having a low content of oxygen and further containing a **solid** composition with high aqueous solubility comprising MAS and an additive is claimed. Also claimed is

a process for preparing a closed container having a low content of oxygen and further containing a **solid** composition comprising MAS and an additive.

ST low oxygen container meiosis activating substance **solid** compn; oocyte fertility stable meiosis activating substance compn container

IT Glycerophospholipids
Proteins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(additive; container with low oxygen content containing a **solid** MAS (meiosis activation substances) composition with an additive for increasing fertility of oocytes and use in IVF or IVM)

IT Meiosis
(container with low oxygen content containing a **solid** MAS (meiosis activation substances) composition with an additive for increasing fertility of oocytes and use in IVF or IVM)

IT Human
(human serum albumin as an additive; container with low oxygen content containing a **solid** MAS (meiosis activation substances) composition with an additive for increasing fertility of oocytes and use in IVF or IVM)

IT Fertilization
(in vitro; container with low oxygen content containing a **solid** MAS (meiosis activation substances) composition with an additive for increasing fertility of oocytes and use in IVF or IVM)

IT Egg
(oocyte; container with low oxygen content containing a **solid** MAS (meiosis activation substances) composition with an additive for increasing fertility of oocytes and use in IVF or IVM)

IT Albumins, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(serum, additive; container with low oxygen content containing a **solid** MAS (meiosis activation substances) composition with an additive for increasing fertility of oocytes and use in IVF or IVM)

IT 516-72-3 19431-20-0, 5 α -Cholesta-8,14-dien-3 β -ol
64284-64-6, 4,4-Dimethyl-5
 α -cholesta-8,14,24-
trien-3 β -ol 174351-75-8
250256-71-4 252892-85-6 330432-44-5 446026-53-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MAS; process and container with low oxygen content and containing a stable MAS (meiosis activation substances) composition for increasing fertility of oocytes and use in IVF or IVM)

L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:208095 CAPLUS

DN 134:242674

TI Composition for in vitro IVF containing a meiosis-activating substance

IN Andersen, Tina Meinertz

PA Novo Nordisk A/s, Den.

SO PCT Int. Appl., 11 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019354	A2	20010322	WO 2000-DK500	20000911
	WO 2001019354	A3	20010614		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1216059	A2	20020626	EP 2000-958274	20000911
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000014058	A	20040330	BR 2000-14058	20000911
	ZA 2002001383	A	20020906	ZA 2002-1383	20020219
	NO 2002001309	A	20020315	NO 2002-1309	20020315
PRA1	DK 1999-1308	A	19990916		
	WO 2000-DK500	W	20000911		
AB	A composition useful in connection with in vitro fertilization (IVF) based on a solid meiosis-activating substance (MAS) or a derivative thereof with low solubility is described. A MAS can be dissolved in an aqueous medium using an				
	additive, e.g., a protein or a phosphoglyceride, to obtain a solution containing at least 0.001 µg/mL and not more than 0.1 g/mL of MAS. For example, solns. were prepared by mixing (a) 100 µL of ethanolic 4,4-dimethyl-5α-cholesta-8,14,24-triene-3β-ol (FF-MAS) containing 5.22, 2.5, or 0.5 µg/mL FF-MAS and (b) 250 µL of 20% aqueous human serum albumin (HSA) in the ratio of FF-MAS to HSA of 1:10,000, 1:6667, and 1:2000, resp., and tested on oocytes obtained from immature female mice. Percent of germinal vesicle breakdown (GVB) for the formulations prepared were 78, 82, and 90%, resp.				
AB	A composition useful in connection with in vitro fertilization (IVF) based on a solid meiosis-activating substance (MAS) or a derivative thereof with low solubility is described. A MAS can be dissolved in an aqueous medium using an				
	additive, e.g., a protein or a phosphoglyceride, to obtain a solution containing at least 0.001 µg/mL and not more than 0.1 g/mL of MAS. For example, solns. were prepared by mixing (a) 100 µL of ethanolic 4,4-dimethyl-5α-cholesta-8,14,24-triene-3β-ol (FF-MAS) containing 5.22, 2.5, or 0.5 µg/mL FF-MAS and (b) 250 µL of 20% aqueous human serum albumin (HSA) in the ratio of FF-MAS to HSA of 1:10,000, 1:6667, and 1:2000, resp., and tested on oocytes obtained from immature female mice. Percent of germinal vesicle breakdown (GVB) for the formulations prepared were 78, 82, and 90%, resp.				
ST	meiosis activating sterol soln fertilization; protein solubilization meiosis activating substance; phosphoglyceride solubilization meiosis activating sterol				
IT	Glycerophospholipids Proteins, general, biological studies				
	RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(solns. containing meiosis-activating substance and additive for in vitro fertilization)				
IT	516-72-3 19431-20-0 64284-64-6		174351-75-8	250256-71-4	
	330432-44-5				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(solns. containing meiosis-activating substance and additive for in vitro				

fertilization)

=> log y

STN INTERNATIONAL LOGOFF AT 09:53:48 ON 01 SEP 2004